McTyre Emory, Helis Corbin A, Farris Michael, Wilkins Lisa, Sloan Darrell, Hinson William H, Bourland J Daniel, Dezarn William A, Munley Michael T, Watabe Kounosuke, Xing Fei, Laxton Adrian W, Tatter Stephen B, Chan Michael D
Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Neurosurgery. 2017 Feb 1;80(2):210-216. doi: 10.1227/NEU.0000000000001227.
Gamma Knife radiosurgery (GKRS) allows for the treatment of intracranial tumors with a high degree of dose conformality and precision. There are, however, certain situations wherein the dose conformality of GKRS is desired, but single session treatment is contraindicated. In these situations, a traditional pin-based GKRS head frame cannot be used, as it precludes fractionated treatment.
To report our experience in treating patients with fractionated GKRS using a relocatable, noninvasive immobilization system.
Patients were considered candidates for fractionated GKRS if they had one or more of the following indications: a benign tumor >10 cc in volume or abutting the optic pathway, a vestibular schwannoma with the intent of hearing preservation, or a tumor previously irradiated with single fraction GKRS. The immobilization device used for all patients was the Extend system (Leksell Gamma Knife Perfexion, Elekta, Kungstensgatan, Stockholm).
We identified 34 patients treated with fractionated GKRS between August 2013 and February 2015. There were a total of 37 tumors treated including 15 meningiomas, 11 pituitary adenomas, 6 brain metastases, 4 vestibular schwannomas, and 1 hemangioma. At last follow-up, all 21 patients treated for perioptic tumors had stable or improved vision and all 4 patients treated for vestibular schwannoma maintained serviceable hearing. No severe adverse events were reported.
Fractionated GKRS was well-tolerated in the treatment of large meningiomas, perioptic tumors, vestibular schwannomas with intent of hearing preservation, and in reirradiation of previously treated tumors.
伽玛刀放射外科手术(GKRS)能够以高度的剂量适形性和精确性治疗颅内肿瘤。然而,在某些情况下,虽然需要GKRS的剂量适形性,但单次治疗是禁忌的。在这些情况下,不能使用传统的基于销钉的GKRS头架,因为它排除了分次治疗。
报告我们使用可重新定位的非侵入性固定系统治疗分次GKRS患者的经验。
如果患者有以下一种或多种适应症,则被认为是分次GKRS的候选者:体积大于10 cc或靠近视路的良性肿瘤、意图保留听力的前庭神经鞘瘤、或先前接受过单次GKRS照射的肿瘤。所有患者使用的固定装置是Extend系统(Leksell伽玛刀Perfexion,医科达公司,斯德哥尔摩昆斯滕斯加坦大街)。
我们确定了2013年8月至2015年2月期间接受分次GKRS治疗的34例患者。共治疗了37个肿瘤,包括15个脑膜瘤、11个垂体腺瘤、6个脑转移瘤、4个前庭神经鞘瘤和1个血管瘤。在最后一次随访时, 所有21例接受视路周围肿瘤治疗的患者视力稳定或改善,所有4例接受前庭神经鞘瘤治疗的患者听力保持良好。未报告严重不良事件。
分次GKRS在治疗大型脑膜瘤、视路周围肿瘤、意图保留听力的前庭神经鞘瘤以及先前治疗过的肿瘤的再照射中耐受性良好。